Close Menu

NEW YORK (GenomeWeb) – Protagen said today it has entered a collaboration with the Gustave Roussy Institute of Oncology to identify biomarkers for immune system-related side effects in cancer patients treated with checkpoint inhibitors.

Under the collaboration, the parties will use Protagen's SeroTag platform, which simultaneously measures autoantibody levels for thousands of antigens, to test cancer immunotherapy patients for markers linked to immune-related adverse events (irAEs) and, ultimately, develop a risk-profiling test for patients undergoing immunotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.